Sigrid Therapeutics is developing an ingested medical device for lowering blood sugar in prediabetics.
Sigrid Therapeutics has raised $4.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2023.
Sigrid Therapeutics's investors include Almi Invest, Joyance Partners, Social Starts, 3T Invest, Irrus Investments.
Sigrid Therapeutics is headquartered in Stockholm, Sweden.
Sigrid Therapeutics is developing an ingested medical device for lowering blood sugar in prediabetics.
Sigrid Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sigrid Therapeutics — Funding & Investors." VCBacked, October 31, 2023, https://www.vcbacked.co/company/sigrid-therapeutics. Accessed July 19, 2026.
VCBacked. (2023). Sigrid Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/sigrid-therapeutics
{{cite web |title=Sigrid Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/sigrid-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated